17827-61-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-methyl-1H-pyrazole-3-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of diverse molecular entities with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 1-methyl-1H-pyrazole-3-carboxylate serves as an essential component in the production of pesticides and other crop protection agents. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases.
Used in Organic Chemistry Reactions:
Methyl 1-methyl-1H-pyrazole-3-carboxylate is employed as a building block in organic chemistry, facilitating the formation of various esters and amides. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules for a range of applications.
Used in Chemical Research:
As a pyrazole derivative, methyl 1-methyl-1H-pyrazole-3-carboxylate is also used in chemical research to explore novel reactions and investigate the properties of pyrazole-containing compounds. This research can lead to the discovery of new chemical processes and the development of innovative materials.

Upstream product

• 67-56-1 methanol 
• 25016-20-0 1-methylpyrazole-3-carboxylic acid 
• 186581-53-3 diazomethane 
• 15366-34-4 methyl 1H-pyrazole 3-carboxylate 
• 922-67-8 propynoic acid methyl ester 
• 158615-33-9 4-Cyano-3-(toluene-4-sulfonyloxy)-4,5-dihydro-3H-[1,2,3]triazole-4-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 
• 1621-91-6 1H-pyrazole-3-carboxylic acid 
• 694-48-4 1,3-dimethyl-1H-pyrazole 

Downstream Products

• 75092-25-0 methyl 4-iodo-1-methyl-1H-pyrazole-3-carboxylate 
• 84547-64-8 3-(chloromethyl)-1-methyl-1H-pyrazole 
• 1142927-97-6 2-(1-methyl-1H-pyrazol-3-yl)acetonitrile 
• 1607024-25-8 (Z)-3-(dimethylamino)-2-(1-methyl-1H-pyrazol-3-yl)acrylonitrile 
• 1607024-26-9 1-methyl-1H,1'H-3,4'-bipyrazol-5'-amine 
• 1607022-82-1 5-(1-ethyl-1H-indazol-5-yl)-3-(1-methyl-1H-pyrazol-3-yl)-4H,7H-pyrazolo[1,5-a]pyrimidin-7-one 
• 1607023-04-0 5-(4-chloro-3-methoxyphenyl)-3-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-34-6 5-(1-methyl-1H-indazol-5-yl)-3-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-49-3 5-(4-chloro-3-(2,2,2-trifluoroethoxy)phenyl)-3-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1616929-90-8 5-(5-cyclopropyl-2-methoxy-phenyl)-N-(3-fluoro-pyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid amide 
• 1616929-92-0 5-(2-Cyclopropyl-5-methyl-pyrimidin-4-yl)-A/-(2,6-difluoro-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid amide 
• 1616930-47-2 C₁₃H₁₃ClN₂O₃ 
• 1616930-48-3 C₁₆H₁₈N₂O₃ 
• 1616930-49-4 C₁₁H₁₁ClN₄O₂ 

Relevant academic research and scientific papers

Adenosine receptor antagonists

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.

HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS

The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

Pyrazolyl-Based Carboxamides I

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS

The Invention relates to pyrazolyl-based carboxamide compounds of formula (l) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.